Titlebook: Blood Stem Cell Transplantation; Jane N. Winter Book 1997 Springer Science+Business Media New York 1997 cell.cytokines.gene therapy.hemato

空隙

書目名稱Blood Stem Cell Transplantation影響因子(影響力)




書目名稱Blood Stem Cell Transplantation影響因子(影響力)學(xué)科排名




書目名稱Blood Stem Cell Transplantation網(wǎng)絡(luò)公開度




書目名稱Blood Stem Cell Transplantation網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Blood Stem Cell Transplantation被引頻次




書目名稱Blood Stem Cell Transplantation被引頻次學(xué)科排名




書目名稱Blood Stem Cell Transplantation年度引用




書目名稱Blood Stem Cell Transplantation年度引用學(xué)科排名




書目名稱Blood Stem Cell Transplantation讀者反饋




書目名稱Blood Stem Cell Transplantation讀者反饋學(xué)科排名

Conjuction

Post-bone marrow transplant use of immunotherapys accumulated over the past few decades and suggests that immune mechanisms are important for eradication of residual disease in the recipient [1–3]. The lack of GVT effect after autologous BMT (ABMT), along with reinfusion of clonogenic tumor cells with the autologous graft, may be responsible for

酷熱

Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell inerapy, with or without radiotherapy, are administered to patients, and normal hematopoiesis is restored with the infusion of normal donor bone marrow. Yet despite intensive conditioning therapy, many patients have residual disease that can result in recurrent leukemia. The prevalence of these residu

ciliary-body

符合國情

The detection of minimal residual disease: implications for bone marrow transplantationndard diagnostic techniques. Therefore, considerable effort has been made over the past decade to develop new techniques that have greatly increased the sensitivity of detection of small numbers of residual neoplastic cells. In particular, the identification of specific gene rearrangements and chrom

挖掘

偏離

松軟

Ex vivo expansion of hematopoietic stem and progenitor cells for transplantationtic cells. Ex vivo expanded hematopoietic cells are useful for a variety of clinical applications such as transplantation, tumor purging, and gene therapy. The anticipated benefits of ex vivo expanded hematopoietic cells over bone marrow or peripheral blood for transplant patients include a shortene

起草

Allogeneic umbilical cord blood transplantationgical malignancies, bone marrow failure syndromes, and selected hereditary immunodeficiency states and metabolic disorders. Use of allogeneic BMT has been limited both by the lack of suitable donors and because of the risk of life-threatening complications that arise when donor and recipient are not

seruting